Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Obstetrics and Gynecology Reports
Erschienen in:

22.07.2017 | Gynecologic Oncology (A Fader, Section Editor)

Emerging Therapies in the Management of High-Grade Serous Ovarian Carcinoma: a Focus on PARP Inhibitors

verfasst von: Karime Kalil Machado, Stéphanie L. Gaillard

Erschienen in: Current Obstetrics and Gynecology Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The aims of this review are to describe key clinical trials that led to Federal Drug Administration (FDA) approval of poly(ADP-ribose) polymerase (PARP) inhibitors for ovarian cancer treatment, contextualize current indications, and to present future perspectives on the use of PARP inhibitors in this setting.

Recent Findings

Since 2014, the FDA has approved three PARP inhibitors for the treatment of relapsed ovarian cancer, initially for patients with BRCA mutations and more recently, for a broader patient population.

Summary

High-grade serous ovarian carcinomas (HGSOC) account for more than 70% of epithelial ovarian cancers. DNA repair is frequently defective in these cancers, and homologous recombination pathway defects are present in approximately 50% of cases. The inhibition of PARP enzymes is a potential synthetic lethal therapeutic strategy for cancers harboring DNA repair defects, including ovarian cancers arising in the presence of BRCA mutations or other forms of homologous recombination deficiency. PARP inhibitors are now an exciting option for the treatment of patients with advanced ovarian cancer. Herein, this topic will be further explored.
Literatur
1.
2.
3.
Cobb LP, Gaillard S, Wang Y, Shih Ie M, Secord AA. Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecol Oncol Res Pract. 2015;2:1.CrossRefPubMedPubMedCentral
4.
Karlan BY, Alvarez RD, Strauss JF 3rd. Evolving paradigms in research and care in ovarian cancers. Obstet Gynecol. 2016;128(4):771–4.CrossRefPubMed
5.
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.
6.
•• Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21. Farmer H et al. and Bryant HE et al. were the first to demonstrate synthetic lethality of PARP inhibitors in BRCA deficiency. CrossRefPubMed
7.
•• Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7. Farmer H et al. and Bryant HE et al. were the first to demonstrate synthetic lethality of PARP inhibitors in BRCA deficiency. CrossRefPubMed
8.
Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer. 2016;115(10):1157–73.CrossRefPubMedPubMedCentral
9.
10.
Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–99.CrossRefPubMedPubMedCentral
11.
12.
Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A. 2011;108(8):3406–11.CrossRefPubMedPubMedCentral
13.
•• Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245–51. Proof-of-concept study that shows safety and efficacy of olaparib in BRCA mutation-associated ovarian cancer. CrossRefPubMed
14.
Kaye SB, Poole CJ, Danska-Bidzinska A, Gianni L, Del Conte G, Gorbunova V, et al. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol. 2013;24(1):145–52.CrossRefPubMed
15.
•• Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852–61. First study to demonstrate activity of a PARP inhibitor in patients with ovarian cancer without germline BRCA mutations. CrossRefPubMed
16.
•• Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–50. This study showed prolonged tumor responses with olaparib in BRCA mutation associated platinum-resistant, heavily pretreated ovarian cancer. CrossRefPubMed
17.
Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199–203.CrossRefPubMed
18.
• Shapira-Frommer ROA, Domchek SM, et al. A phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation. Eur J Cancer. 2015;51:S545. Study demonstrating robust antitumor activity of rucaparib in heavily pretreated ovarian cancer with BRCA mutations. CrossRef
19.
•• Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87. Phase II study that embased FDA approval of rucaparib for ovarian cancer treatment and proposed a tumor-based approach to select patients who would benefit from treatment. CrossRefPubMed
20.
• Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation—an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015;137(3):386–91. Single-agent activity of veliparib was demonstrated in BRCAm relapsed ovarian cancer. CrossRefPubMedPubMedCentral
21.
•• Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92. This randomized study shows improved PFS in recurrent, platinum-sensitive ovarian cancer treated with olaparib maintenance. CrossRefPubMed
22.
•• Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64. This study showed progression-free survival improvement with niraparib maintenance for recurrent, platinum-sensitive ovarian cancer, regardless of BRCA status. CrossRefPubMed
23.
•• Pujade-Lauraine E, Ledermann J, Penson RT, Oza AM, Korach J, Huzarski T, et al. Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Society of Gynecologic Oncology annual meeting on Women’s Cancer (SGO); National Harbor, Maryland.2017. First phase III trial of olaparib as maintenance treatment in recurrent, platinum-sensitive, BRCAm ovarian cancer, which confirmed a PFS benefit.
24.
•• Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–14. First study to demonstrate a PFS benefit with the combination of an anti-angiogenic and a PARP inhibitor for platinum-sensitive ovarian cancer treatment. CrossRefPubMedPubMedCentral
25.
• Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34. First study to show antitumor activity of PARP inhibitors in patients with BRCA mutation-associated tumors. CrossRefPubMed
26.
• Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512–9. This study shows correlation between PARP inhibitor activity and platinum sensitivity in patients with BRCA mutation-associated tumors. CrossRefPubMed
27.
Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 2015;21(19):4257–61.CrossRefPubMed
28.
•• Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–61. This study shows that patients with platinum-sensitive ovarian cancer and a BRCA mutations derive greatest benefit with olaparib maintenance. CrossRefPubMed
29.
30.
31.
•• Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579–89. Final overall survival analysis of a trial of olaparib maintenance in patients with recurrent platinum-sensitive ovarian cancer and shows a survival advantage for BRCAm patients. CrossRefPubMed
32.
Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer. 2016;115(11):1313–20.CrossRefPubMed
33.
Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. 2016;114(12):e21.CrossRefPubMedPubMedCentral
34.
Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso PM, Patel M, et al. A phase I-II study of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017;
35.
36.
Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882–92.CrossRefPubMed
37.
Puhalla SL, Beumer JH, Pahuja S. Final results of a phase 1 study of single-agent veliparib in patient with either BRCA1/2-mutated cancer, platinum-refractory ovarian, or basal-like breast cancer. J Clin Oncol. 2014;32:5s. (Abstract 2570)
38.
Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19(18):5003–15.CrossRefPubMed
39.
Wainberg ZA, Hecht JR, Konecny GE, Goldman JW, Sadeghi S, Chmielowski B, et al. Safety and efficacy results from a phase I dose-escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignancies. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res. 2016;76(14 Suppl):abstract CT011.
40.
de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov. 2017;7(6):620–9.
41.
Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180–6.CrossRefPubMed
42.
Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165–71.CrossRefPubMed
43.
• Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, et al. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013;49(14):2972–8. This study showed increased antitumor activity with the combination of an anti-angiogenic and a PARP inhibitor. CrossRefPubMedPubMedCentral
44.
Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22(3):393–402.CrossRefPubMed
45.
McAlpine JN, Porter H, Kobel M, Nelson BH, Prentice LM, Kalloger SE, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012;25(5):740–50.CrossRefPubMed
46.
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–43.CrossRefPubMedPubMedCentral
47.
Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015;3(11):1257–68.CrossRefPubMedPubMedCentral
48.
Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2012;18(6):1726–34.CrossRefPubMedPubMedCentral
49.
LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors. Clin Cancer Res. 2016;22(13):3227–37.CrossRefPubMedPubMedCentral
50.
Tan AR, Toppmeyer D, Stein MN, Moss RA, Gounder M, Lindquist DC, et al. Phase I trial of veliparib (ABT-888), a poly(ADP-ribose)polymerase (PARP) inhibitor in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors. J Clin Oncol. 2011;29:3041. (Suppl.: abstract 3041) CrossRef
51.
Reiss KA, Herman JM, Armstrong D, Zahurak M, Fyles A, Brade A, et al. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. Gynecol Oncol. 2017;144(3):486–90.CrossRefPubMed
52.
Reiss KA, Herman JM, Zahurak M, Brade A, Dawson LA, Scardina A, et al. A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. Clin Cancer Res. 2015;21(1):68–76.CrossRefPubMed
53.
Bell-McGuinn KM, Brady WE, Schilder RJ, Fracasso PM, Moore KM, Walker JL, et al. A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015;33:5507. (Abstract 5507)
54.
Landrum LM, Brady WE, Armstrong DK, Moore KN, DiSilvestro PA, O'Malley DM, et al. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016;140(2):204–9.CrossRefPubMed
55.
Konner JA, Boucicaut NN, O’Cearbhaill RE. A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adnexal carcinoma. J Clin Oncol. 2017;35 (suppl; abstr 5572).
56.
Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16(1):87–97.
Metadaten
Titel
Emerging Therapies in the Management of High-Grade Serous Ovarian Carcinoma: a Focus on PARP Inhibitors
verfasst von
Karime Kalil Machado
Stéphanie L. Gaillard
Publikationsdatum
22.07.2017
Verlag
Springer US
Erschienen in
Current Obstetrics and Gynecology Reports / Ausgabe 3/2017
Elektronische ISSN: 2161-3303
DOI
https://doi.org/10.1007/s13669-017-0215-1

Weitere Artikel der Ausgabe 3/2017

Contemporary Treatment Strategies for Rare Epithelial Ovarian Cancers

  • Gynecologic Oncology (A. Fader, Section Editor)

HPV Vaccination: Are We Meeting Our Targets in Cervical Cancer Prevention?

  • Gynecologic Oncology (A Fader, Section Editor)

Conventional Laparoscopy vs. Robotic-Assisted Laparoscopy for Sacrocolpopexy and Sacrocervicopexy: a Review

  • Urogynecology (S Pulliam and N Kohli, Section Editors)

Bleeding Associated with Hormonal Contraceptives: Understanding and Managing a Common Problem

  • Family Planning (A Burke, Section Editor)

Improvements in Contraception for Adolescents

  • Family Planning (A Burke, Section Editor)

Defecatory Dysfunction and the Pelvic Floor

  • Urogynecology (S Pulliam and N Kohli, Section Editors)

Neu im Fachgebiet Gynäkologie und Geburtshilfe

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Einer von sieben Frauen macht die Menopause sehr zu schaffen

Von mäßigen bis schweren vasomotorischen Beschwerden sind 14,7% der Frauen in der Postmenopause betroffen. Das haben kanadische Forscherinnen in einer Subgruppenanalyse der WARM-Studie herausgefunden.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Keine eingeschränkten Kassenleistungen bei Schwangerschaft nach IVF

Nach privat bezahlter In-vitro-Fertilisation muss die gesetzliche Krankenkasse ein Arzneimittel zum Erhalt der Schwangerschaft bezahlen, so ein Urteil des Sozialgerichts in München.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise